

Investor News

Markus Georgi
Senior Vice President
Investor Relations & Sustainability

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Deutschland
T +49 6172 608-2485
F +49 6172 608-2488
markus.georgi@fresenius.com
www.fresenius.de

April 7, 2020

Fresenius Kabi takes comprehensive measures to increase supply of essential drugs during COVID-19 pandemic

- **Production of critical drugs scaled up with priority supply for COVID-19 patients**
- **Commitment to price stability for essential drugs for COVID-19 patients during pandemic**

Fresenius Kabi is responding to the significant increase in worldwide demand for essential drugs for the treatment of COVID-19 patients, especially medicines used for sedation such as Propofol and pain management drugs. The company is maximizing supply with all compatible manufacturing capacity now dedicated to these vital drugs. Fresenius Kabi has made significant, future-oriented investments in recent years into both automation and capacity in its manufacturing facilities; these are now enabling treatment for more patients worldwide.

Fresenius Kabi will continue to align its manufacturing capacities to the dynamically developing demand resulting from the COVID-19 pandemic.

Fresenius Kabi is dedicated to protecting its workforce in all aspects and has introduced increased safety measures for employees across the organization. These safeguards will also facilitate continued operations at its production sites. To ensure uninterrupted access to the company's medicines, devices and technologies Fresenius Kabi is working closely with governments and public health authorities around the world.

Stephan Sturm, CEO of Fresenius, said: "The COVID-19 pandemic poses particular challenges for our society. As a healthcare company whose mission is to offer better and affordable medicine to ever more people, we have a special responsibility that we will live up to also during these testing times. Irrespective of demand beyond our ability to supply, we commit ourselves to keeping prices for essential drugs for COVID-19 patients stable during this pandemic. My special thanks go to our employees around the world. I am very grateful for their extraordinary commitment."

Mats Henriksson, CEO of Fresenius Kabi, said: "Our purpose is to put lifesaving medicines and technologies in the hands of healthcare professionals and to find answers to the challenges they face. This purpose has never been more important than today. We do whatever is possible to further increase manufacturing output and the supply of urgently needed products. I am inspired by the dedication of our employees who are committed to maintaining the supply of our medicines to patients and their families."

#

Fresenius is a global health care group, providing products and services for dialysis, hospital and outpatient medical care. In 2019, Group sales were €35.4 billion. On December 31, 2019, the Fresenius Group had 294,134 employees worldwide.

For more information visit the Company's website at www.fresenius.com.

Follow us on Twitter: www.twitter.com/fresenius_ir.

Follow us on LinkedIn: www.linkedin.com/company/fresenius-investor-relations

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA

Registered Office: Bad Homburg, Germany

Commercial Register: Amtsgericht Bad Homburg, HRB 11852

Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE

Registered Office: Bad Homburg, Germany

Commercial Register: Amtsgericht Bad Homburg, HRB 11673

Management Board: Stephan Sturm (Chairman), Dr. Francesco De Meo, Rachel Empey, Dr. Jürgen Götz, Mats Henriksson, Rice Powell, Dr. Ernst Wastler

Chairman of the Supervisory Board: Dr. Gerd Krick